SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.61-0.7%4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1370)7/29/2002 5:34:34 PM
From: Arthur Radley  Read Replies (1) of 1475
 
On the surface this announcement is positive in that for sure they are taking a more sound business approach to their operation.
1) Like the accelrated Eligix sales, but until they get this approved in the US....no great potential IMO.
2)Revamping AlloMune strategy leaves me wondering...why the addition of kits consisting of siplizumab IN COMBINATION with products that have already been approved. Is this an admission that siplizumab isn't the drug we thought?

Finally, and the thought that really concerns me....is this action the result of coming bad news from MEDI on MEDI-507. Have they given up on the new indication for the drug? And why the long and drawn out analysis of the current data....waiting to October to present the data in Prague is bothersome.

Tomorrows conference call should be interesting!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News